Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Embraces PARP Promise With Tesaro Buy

Executive Summary

The UK major is marking its return to oncology by spending over $5bn to get hold of Tesaro and its PARP inhibitor Zejula. The question now is whether it will be able to catch AstraZeneca's market-leading Lynparza.

Advertisement

Related Content

Crown Labs Spreads Out, GSK Narrows Focus In OTC Skin Care Brand Deal
Crown Labs Spreads Out, GSK Narrows Focus In OTC Skin Care Brand Deal
Deal Watch: Boehringer Teams Up In CNS Disorders Again, This Time With Domain
Crown Labs Spreads Out, GSK Narrows Focus In OTC Skin Care Brand Deal
AZ's Lynparza PARP Lead Likely To Lengthen With FDA Priority Review
QUADRA Supports Broader Use For Tesaro's PARP Inhibitor Zejula

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124271

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel